Mergers & Acquisitions Mergers & Acquisitions

Danaher asked to divest assets, commit to R&D for GE Biopharma takeover in China decision

By Yonnex Li
  • 02 Mar 2020 00:50
  • 02 Mar 2020 01:24
US medical-equipment maker Danaher’s takeover of GE's biopharma unit has been approved by China's antitrust regulator, conditioned on a package of remedies including divestitures to mitigate the deal's impact on competition.
Notably, Washington, DC-based Danaher is required to commit to a research and development project for at least two years

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Yonnex Li

Chief Correspondent, Greater China

Yonnex has an MA in Journalism from the Chinese University of Hong Kong, after obtaining a BA in Translation at the same university. At MLex, she writes extensively on antitrust developments in the Greater China region, including investigations, court cases and merger control of international transactions. Prior to joining MLex, she worked as a reporter at the English division of the Hong Kong Economic Journal, providing coverage and analysis on China's banking sector, asset management industry as well as currency and financial reforms.

Discover MLex

Stay on top of global regulatory developments

Latest News